PharmaShots | Incisive News in 3 Shots

Subscribe Now

TORTUGA study

Gilead and Galapagos NV's Filgotinib (JAK1i) Achieves Primary Endpoints for P-II TORTUGA study in AS patients

Gilead and Galapagos NV's Filgotinib (JAK1i) Achieves Primary Endpoints for P-II TORTUGA study in AS patients

September 6, 2018

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us